Genzyme Bid For Impath Unit Reflects Efforts To Raise Oncology Profile
This article was originally published in The Gray Sheet
Executive Summary
Genzyme will gain access to an expanded menu of cancer diagnostic tests and physician services if a pending $215 mil. cash bid for Impath's cancer testing unit proves successful